Platelet preservation package comprising a short to ultra-short acting antiplatelet agent and anticoagulant with an oxygen carrier

• US 8,142,992 B2
• Filed: 05/08/2009
• Issued: 03/27/2012
• Est. Priority Date: 01/12/2005
• Status: Active Grant

• Current Assignee: Biovec Transfusion LLC
• Original Assignee: Biovec Transfusion LLC
• Inventors: Sehgal, Lakshman R., Mousa, Shaker
• Primary Examiner(s): SAUCIER, SANDRA E
• Application Number:
  US12/437,874
• Publication Number:
  US 20090263781A1
• Time in Patent Office: 1,054 Days
• Field of Search: None
• US Class Current: 435/2
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A01N 1/0215 Disinfecting agents, e.g. antimicrobials for preserving living parts
• CPC Class Codes: A01N 1/0226 Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients

Abstract

The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Claims

1. A platelet preservation package, comprising:

a platelet preservation composition comprising;

a short-to-ultra-short acting antiplatelet agent;

a short-to-ultra-short acting anticoagulant;

an oxygen carrier selected from the group consisting of hemoglobin, ferroprotoporphyrin, perfluorochemicals, and mixtures thereof; and

a container for storing the platelet preservation composition.

2. The platelet preservation package of claim 1, wherein said antiplatelet agent is capable of reversibly blocking platelet activation and/or aggregation by blocking sites on the platelet surface.

3. The platelet preservation package of claim 1, wherein said antiplatelet agent is capable of binding to, or associating with a GPIIb/IIIa receptor site.

4. The platelet preservation package of claim 1, wherein said antiplatelet agent is selected from the group consisting of DUP728, XJ757, XR299, eptifibatide, orbofiban, xemilofiban, lamifiban, tirofiban, and mixtures thereof.

5. The platelet preservation package of claim 1, wherein said antiplatelet agent is selected from the group consisting of linear and cyclic RGD-containing peptides.

6. The platelet preservation package of claim 5, wherein said linear and cyclic RGD-containing peptides are conjugated to a Nitric oxide donor.

7. The platelet preservation package of claim 1, wherein said antiplatelet agent is a pharmaceutically acceptable antiplatelet agent and has a circulating half-life of inhibition of about less than 4 hours.

8. The platelet preservation package of claim 1, wherein said antiplatelet agent comprises about 0.001 mg to about 5 mg of a GPIIb/IIIa inhibitor.

9. The platelet preservation package of claim 1, wherein said anticoagulant is a compound that reversibly inhibits factor Xa, or factor IIa, or both.

10. The platelet preservation package of claim 9, wherein said anticoagulant is a short-to-ultra-short acting IIa inhibitor, and wherein said short-to-ultra-short acting IIa inhibitor is selected from the group consisting of hirudin, hirulog, melgatran, and combinations thereof.

11. The platelet preservation package of claim 9, wherein said anticoagulant is a pharmaceutically acceptable anticoagulant and is a combination of at least one short-to-ultra-short acting IIa inhibitor, and at least one short-to-ultra-short acting Xa inhibitor.

12. The platelet preservation package of claim 9, wherein said anticoagulant is a short-to-ultra-short acting Xa inhibitor with a circulating half-life of less than 4 hours.

13. The platelet preservation package of claim 12, wherein said anticoagulant is selected from the group consisting of DX-9065a, BX-80783, RPR-120844, and short-to-ultrashort acting Xa inhibitors.

14. The platelet preservation package of claim 1, wherein said antiplatelet agent is a compound that binds to or associates with GPIIb/IIIa sites, and wherein the anticoagulant is a factor Xa inhibitor, a factor IIa inhibitor, or a combination of both.

15. The platelet preservation package of claim 1, wherein said oxygen carrier is a hemoglobin-based oxygen carrier.

16. The platelet preservation package of claim 15, wherein said hemoglobin-based oxygen carrier is substantially free of red cell membrane contaminants.

17. The platelet preservation package of claim 1, wherein the preserved platelet composition further comprises a short-to-ultrashort acting broad spectrum anti-microbial agent selected from the group consisting of:

penicillin, monobactam, cephalosporin, carbapenems, vancomycin, isoniazid, ethambutol, aminoglycoside, tetracycline, chloramphenicol, macrolide, rifamycin, quinolone, fluoroquinolone, sulfonamide, polyene antibiotic, imidazole, triazole, griseofulvin and combinations thereof.

18. The platelet preservation package of claim 1, wherein the container is an oxygen-permeable bag.

19. The platelet preservation package of claim 1, wherein the container is an oxygen-impermeable bag.